CancerDrs Find care

Multiple Myeloma clinical trials in New Mexico

8 actively recruiting multiple myeloma trials at 5 sites across New Mexico.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04566328
Sites in New Mexico:
  • University of New Mexico Cancer Center — Albuquerque, New Mexico
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are consid…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05561387
Sites in New Mexico:
  • Lovelace Medical Center-Saint Joseph Square — Albuquerque, New Mexico
  • University of New Mexico Cancer Center — Albuquerque, New Mexico
  • Presbyterian Kaseman Hospital — Albuquerque, New Mexico
  • Presbyterian Rust Medical Center/Jorgensen Cancer Center — Rio Rancho, New Mexico
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexam…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05552222
Sites in New Mexico:
  • Christus St. Vincent Regional Cancer Center — Santa Fe, New Mexico
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple m…

Sponsor: Celgene
NCT ID: NCT05519085
Sites in New Mexico:
  • University of New Mexico Comprehensive Cancer Center — Albuquerque, New Mexico
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, inclu…

Sponsor: Kite, A Gilead Company
NCT ID: NCT06413498
Sites in New Mexico:
  • New Mexico Cancer Research Alliance — Albuquerque, New Mexico
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…

Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in New Mexico:
  • Lovelace Medical Center - Saint Joseph Square — Albuquerque, New Mexico
  • Presbyterian Kaseman Hospital — Albuquerque, New Mexico
  • The University of New Mexico Comprehensive Cancer Center — Albuquerque, New Mexico
  • Memorial Medical Center — Las Cruces, New Mexico
  • Presbyterian Rust Medical Center — Rio Rancho, New Mexico
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants w…

Sponsor: Sanofi
NCT ID: NCT06356571
Sites in New Mexico:
  • San Juan Oncology Associates- Site Number : 8400016 — Farmington, New Mexico
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in New Mexico:
  • Lovelace Medical Center-Saint Joseph Square — Albuquerque, New Mexico
  • University of New Mexico Cancer Center — Albuquerque, New Mexico
  • Lovelace Women's Hospital — Albuquerque, New Mexico
  • Presbyterian Kaseman Hospital — Albuquerque, New Mexico
  • Memorial Medical Center-Las Cruces — Las Cruces, New Mexico
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20